Cerenis's CER-001 heading for Phase II with €51 million in new funds
This article was originally published in Scrip
Executive Summary
Cerenis Therapeutics has raised a total of €50.7 million, with more funding to come this year, to take its lead programme through Phase II clinical trials and advance the development of other pipeline products to treat atherosclerosis.